---
canonical_url: https://www.stockexpertai.com/earnings/jnj
last_updated: 2026-07-18T06:12:49.999Z
---

# Johnson & Johnson (JNJ) Q1 FY2027 Earnings Preview

> This content was automatically generated with FMP live data + Q2 FY2026 earnings call transcript. Generated: 2026-07-18T06:12:47.928Z. Educational tool, not investment advice.

---

## Quick Summary

| Field | Value | Source |
|---|---|---|
| Price | $253.04 (▲ 1.23%) | fmp:quote |
| Market Cap | $609.1B | fmp:profile |
| 52w range | $162.78 – $269.43 | fmp:quote |
| Earnings | Tue 13 Oct | fmp:earnings-history |
| EPS estimate | $3.02 (+8% YoY) | fmp:earnings-estimate |
| Revenue estimate | $25.3B | fmp:earnings-estimate |
| Beat streak | 2/4 | fmp:earnings-history |
| Rating | B+ (overall 3/5) | fmp:ratings |
| Analyst median target | $272 (+7.5% upside) | fmp:price-target-consensus |
| MoonshotScore | 60/100 | derived |
| Council | 3/6 bullish | derived |
| Munger verdict | Fairly Valued | derived |

## Johnson & Johnson — Q1 FY2027 Expectations

Q1 consensus: revenue <strong data-source="fmp:earnings-estimate" data-field="estimates.next.revenueAvgLabel">$25.3B</strong><sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.revenueAvg" title="FMP est">[FMP est]</sup>, EPS <strong data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">$3.02</strong><sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg" title="FMP est">[FMP est]</sup>. 2 consecutive quarters of beat<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.beatStreakCount" title="FMP earnings">[FMP earnings]</sup>.

## Quick Take

**Score:** B+ · **Stance:** HOLD · **Council:** 3/6 · **Moonshot:** 60

= MoonshotScore <strong>60</strong><sup class="cite" data-source="derived" data-field="moonshot.score" title="multi-pillar formula">[multi-pillar formula]</sup> + Council <strong>3/6</strong><sup class="cite" data-source="derived" data-field="council.bullishCount" title="6-lens rule">[6-lens rule]</sup>. Form 4: 0 transactions<sup class="cite" data-source="fmp:insider-trading" data-field="insider.txCount" title="FMP Form 4">[FMP Form 4]</sup>.

## Watchlist (0 metrics)

—

## MoonshotScore Pillars

| Pillar | Score | Level | Evidence |
|---|---|---|---|
| Revenue Growth | 3.0 | weak | Q2 vs Q3: moderate growth (+5.5%) |
| Gross Margin | 7.0 | strong | Q2: very high margin (73.1%, software/cloud territory) |
| Operating Leverage | 3.0 | weak | op margin healthy (28.3%) |
| Cash Runway | 10.0 | strong | FCF strong ($1.5B FCF, covers CapEx) |
| R&D Intensity | 5.0 | medium | high R&D intensity (15.4%, aggressive) |
| Price Momentum | 7.0 | strong | RSI 54.4 balanced, 50d above |
| News Sentiment | 7.0 | strong | majority buy (65%) |

**Formula:** sum(pillar.score) / (count * 10) * 100. Each pillar deterministic from FMP. Source maps in pillar.formula.

## Council (7-Lens)

| Name | Stance | Context |
|---|---|---|
| Ray Dalio | bull | macro · target upside +7.5% |
| Ken Griffin | bull | flow · 50d MA above |
| Jim Simons | neutral | quant · RSI 54 |
| Klarman | neutral | value · target upside +7.5% |
| Buffett | bull | quality · ROE score 5/5 |
| Munger | neutral | valuation · target upside +7.5% |

**Formula:** Each lens uses deterministic rule on bundle data. Logged in member.contextTr.

## Munger Lens

- **Verdict:** Fairly Valued
- **Financial Health:** Moderate
- **Margin of Safety:** Weak
- **Interest Coverage:** Adequate
- **ROIC vs WACC:** Healthy

**Formula:** verdict=upside>25?Undervalued:>0?Fairly Valued:Overvalued. Each lens deterministic from FMP ratings + priceTarget.

## Technical Levels

- **RSI(14):** 54.4 — dengeli — yön sinyali zayıf
- **50d MA:** $239 — hisse %6.0 üstünde — kısa vadeli destek
- **200d MA:** $223 — hisse %13.5 üstünde — uzun vadeli destek
- **Volume (10d):** -5%

## Past Performance (4 Quarters)

| Quarter | EPS Actual | EPS Estimate | Result | Reaction |
|---|---|---|---|---|
| Q3 FY25 | $2.80 | $2.76 | BEAT | +0.2% |
| Q4 FY25 | $2.46 | $2.46 | MISS | +0.2% |
| Q1 FY26 | $2.70 | $2.68 | BEAT | -0.6% |
| Q2 FY26 | $2.90 | $2.84 | +2.1% EPS | +1.2% |

Q2 (July 15, 2026): EPS $2.90 vs $2.84 est<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.history.0" title="FMP">[FMP]</sup>, +2.1% beat. D+1 movement: +1.2%<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.timeline.3.reactionLabel" title="FMP D+1">[FMP D+1]</sup>. Decline despite beat — market reacted to guidance, not numbers.

## 3 Scenarios

### Scenario A · Beat
**Q1 EPS > $3.02 + CapEx discipline**

Threshold: EPS > $3.02<sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">[FMP est]</sup>.

Target: Break above median target $272<sup class="cite" data-source="fmp:price-target-consensus" data-field="priceTarget.median">[FMP target]</sup>; high target $305<sup class="cite" data-source="fmp:price-target-consensus" data-field="priceTarget.high">[FMP]</sup> upper bound.

### Scenario B · In-Line
**EPS ≈ $3.02 + CapEx < $1.0B**

Threshold: EPS ≈ $3.02<sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">[FMP est]</sup>, Q1 CapEx < $1.0B<sup class="cite" data-source="fmp:cashflow" data-field="cashflow.qPrev.capexLabel">[FMP]</sup>.

Target: Consolidation in the band between current $253<sup class="cite" data-source="fmp:quote" data-field="quote.price">[FMP]</sup> and median $272<sup class="cite" data-source="fmp:price-target-consensus" data-field="priceTarget.median">[FMP]</sup>.

### Scenario C · Miss
**EPS < $2.93 or CapEx ≥ $1.0B**

Threshold: EPS < $2.93<sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">[FMP est×0.97]</sup>.

Target: Current $253 below SMA200 $223<sup class="cite" data-source="fmp:technical" data-field="technical.sma200">[FMP]</sup>, if rejection continues, $189<sup class="cite" data-source="derived" data-field="technical.sma200" data-formula="round(sma200*0.85)">[derived]</sup> support activates.

## Risk Notes

### Primary segment below threshold
Q2: EPS $2.90 vs $2.84 beat<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.history.0" title="FMP">[FMP]</sup>, stock +1.2% D+1<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.timeline.3.reactionLabel" title="FMP">[FMP]</sup>.

### Backlog concentration
No RPO/backlog concentration disclosed in Q2 earnings call.

### Insider trading
Form 4 data is marked in the table — this page does not generate assumptions for this stock.

| Executive | Action | Amount | Date |
|---|---|---|---|


**Net:** — (0 transactions · 0 sells · 0 buys) · Q2 FY26

### CapEx shock
Q2 CapEx $1.0B<sup class="cite" data-source="fmp:cashflow" data-field="cashflow.qPrev.capexLabel" title="FMP cashflow">[FMP cashflow]</sup>. Q2 op margin 28.3%<sup class="cite" data-source="fmp:income" data-field="income.quarters.0.operatingMargin" title="FMP op margin">[FMP op margin]</sup> — this level in Q1 is sensitive to CapEx revision risk.

## Wall Street Consensus

- **Median target:** $272 (+7.5% upside vs current $253)
- **High / Low:** $305 / $220
- **Buy / Hold / Sell:** 15 / 7 / 1
- **Analyst count:** 15 (last quarter), 96 all-time

## Additional Transcript Insights

—

---

*Data source: FMP (live query, 2026-07-18), Q2 FY2026 earnings call transcript (Translated to EN with Gemini 2.0 Flash). Educational tool, not investment advice.*